Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
2.
JDS Commun ; 2(2): 80-85, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-36338776

RESUMO

Within seasonal dairy systems, cows that calve late in the calving season are less likely to become pregnant and maintain a yearly calving interval. Very few studies have examined effective strategies for reproductive management of these late-calving cows. The objectives were to evaluate the reproductive performance of early- and late-calving dairy cows that were either inseminated after observed estrus (control) or enrolled in a timed AI and resynchronization protocol [progesterone (P4) Ovsynch Resynch)]. Early-calving cows calved during the first week of the calving season, whereas late-calving cows calved after 6 wk but were at least 10 d in milk at study commencement. Three dairy herds participated in the study with 391 cows total. Within each calving group, cows were randomly assigned to P4 Ovsynch Resynch or control (no treatment) in a 2 × 2 experimental design. Artificial insemination continued for 6 wk after mating start date (MSD) and was followed by 6 wk of natural service. The interval from MSD to AI was shorter (11.7 vs. 14.7 d) and the 3-wk pregnancy rate (49.5 vs. 21.2%) and the 6-wk pregnancy rate (60.8 vs. 42.4%) were greater in the early-calving compared with the late-calving control cows. By design, synchronized cows received timed AI on MSD and were not included in the statistical analysis of submission rate and interval from MSD to AI. The proportion of cows that received a second AI was not increased by the progesterone-based resynchronization strategy but was greater in early-calving compared with late-calving cows. The 12-wk pregnancy rate was greater (64.5 vs. 45.0%) in the early-calving synchronized cows compared with the late-calving synchronized cows. The interval from MSD to pregnancy was 6 and 12.6 d shorter for synchronized compared with control cows in the early- and late-calving groups, respectively. The results demonstrated reduced reproductive performance of late-calving cows compared with early-calving cows. Nonetheless, a major improvement to reproductive performance was achieved by targeting late-calving cows with a synchronization program, even when cows were only 20 to 50 DIM at first AI. Resynchronization of estrus with a progesterone device only, however, was not sufficient to increase the proportion of nonpregnant cows that received a second AI.

3.
Rev Sci Tech ; 39(2): 523-531, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-33046923

RESUMO

A lack of human and material resources can limit effective responses to animal disease emergencies. Drawing upon examples from Australia and New Zealand, this paper proposes a framework for identifying human and material resources and securing the necessary personnel and materials before or during an animal disease emergency. This staged process involves: a) assessing the nature of the risks to be managed, b) identifying the types of resources required, c) assessing available resources and identifying gaps and d) developing arrangements to ensure availability of resources. It discusses the advantages and disadvantages of different strategies to secure access to human and material resources, including whole-of-government arrangements to access other government resources, national and international reserve models for responders, just-in-time employment and purchase of materials, and purchase of stockpiles.


La disponibilité insuffisante des ressources tant humaines que matérielles peut limiter l'efficacité des interventions en cas d'urgence zoosanitaire. À partir de l'expérience acquise par l'Australie et la Nouvelle-Zélande, les auteurs proposent un cadre permettant d'inventorier les ressources humaines et matérielles et de garantir la disponibilité des personnels et des équipements nécessaires avant ou pendant une urgence zoosanitaire. Le processus par étapes proposé prévoit : a) d'évaluer la nature des risques qu'il conviendra de traiter ; b) d'identifier les types de ressources à mobiliser ; c) d'évaluer les ressources disponibles et les lacunes ; d) de prendre les dispositions nécessaires pour garantir la disponibilité opérationnelle des ressources. Les auteurs examinent les avantages et les inconvénients respectifs de diverses stratégies visant à se doter des ressources humaines et matérielles nécessaires, en particulier les dispositions gouvernementales permettant de réquisitionner d'autres ressources publiques, les schémas nationaux et internationaux d'intervenants réservistes, les dispositifs d'emploi et d'achats de matériel à flux tendus et la constitution de stocks stratégiques.


La cantidad de recursos humanos y materiales disponibles puede ser un factor limitante a la hora de responder eficazmente a las emergencias zoosanitarias. Partiendo de ejemplos tomados de Australia y Nueva Zelanda, los autores proponen un marco de referencia para determinar los recursos humanos y materiales necesarios y asegurarse de contar con ellos antes o en el curso de una emergencia zoosanitaria. Se trata de un proceso por etapas, que pasa por: a) evaluar la naturaleza de los riesgos que hay que manejar; b) determinar los tipos de recursos que se requieren; c) determinar los recursos disponibles y los faltantes; y d) concebir e implantar disposiciones para asegurarse de tener disponibles todos esos recursos. Los autores pasan revista a las ventajas e inconvenientes de distintos procedimientos para asegurarse el acceso a recursos humanos y materiales, tales como: la aplicación de disposiciones que, abarcando todas las instancias gubernamentales, garanticen el acceso a recursos de otras instancias públicas; los modelos de personal reservista nacional e internacional; los métodos de contratación y compra de material «justo a tiempo¼ (just-in-time); o la adquisición por adelantado de existencias de reserva.


Assuntos
Doenças dos Animais , Animais , Austrália , Emergências/veterinária , Governo , Humanos , Nova Zelândia
4.
J Steroid Biochem Mol Biol ; 155(Pt B): 245-51, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26554936

RESUMO

BACKGROUND: Two vitamin D pregnancy supplementation trials were recently undertaken in South Carolina: The NICHD (n=346) and Thrasher Research Fund (TRF, n=163) studies. The findings suggest increased dosages of supplemental vitamin D were associated with improved health outcomes of both mother and newborn, including risk of preterm birth (<37 weeks gestation). How that risk was associated with 25(OH)D serum concentration, a better indicator of vitamin D status than dosage, by race/ethnic group and the potential impact in the community was not previously explored. While a recent IOM report suggested a concentration of 20 ng/mL should be targeted, more recent work suggests optimal conversion of 25(OH)D-1,25(OH)2D takes place at 40 ng/mL in pregnant women. OBJECTIVE: Post-hoc analysis of the relationship between 25(OH)D concentration and preterm birth rates in the NICHD and TRF studies with comparison to Charleston County, South Carolina March of Dimes (CC-MOD) published rates of preterm birth to assess potential risk reduction in the community. METHODS: Using the combined cohort datasets (n=509), preterm birth rates both for the overall population and for the subpopulations achieving 25(OH)D concentrations of ≤20 ng/mL, >20 to <40 ng/mL, and ≥40 ng/mL were calculated; subpopulations broken down by race/ethnicity were also examined. Log-binomial regression was used to test if an association between 25(OH)D serum concentration and preterm birth was present when adjusted for covariates; locally weighted regression (LOESS) was used to explore the relationship between 25(OH)D concentration and gestational age (weeks) at delivery in more detail. These rates were compared with 2009-2011 CC-MOD data to assess potential risk reductions in preterm birth. RESULTS: Women with serum 25(OH)D concentrations ≥40 ng/mL (n=233) had a 57% lower risk of preterm birth compared to those with concentrations ≤20 ng/mL [n=82; RR=0.43, 95% confidence interval (CI)=0.22,0.83]; this lower risk was essentially unchanged after adjusting for covariates (RR=0.41, 95% CI=0.20,0.86). The fitted LOESS curve shows gestation week at birth initially rising steadily with increasing 25(OH)D and then plateauing at ∼40 ng/mL. Broken down by race/ethnicity, there was a 79% lower risk of preterm birth among Hispanic women with 25(OH)D concentrations ≥40 ng/mL (n=92) compared to those with 25(OH)D concentrations ≤20 ng/mL (n=29; RR=0.21, 95% CI=0.06,0.69) and a 45% lower risk among Black women (n=52 and n=50; RR=0.55, 95% CI=0.17,1.76). There were too few white women with low 25(OH)D concentrations for assessment (n=3). Differences by race/ethnicity were not statistically significant with 25(OH)D included as a covariate. Compared to the CC-MOD reference group, women with serum concentrations ≥40 ng/mL in the combined cohort had a 46% lower rate of preterm birth overall (n=233, p=0.004) with a 66% lower rate among Hispanic women (n=92, p=0.01) and a 58% lower rate among black women (n=52, p=0.04). CONCLUSIONS: In this post-hoc analysis, achieving a 25(OH)D serum concentration ≥40 ng/mL significantly decreased the risk of preterm birth compared to ≤20 ng/mL. These findings suggest the importance of raising 25(OH)D levels substantially above 20 ng/mL; reaching 40 ng/mL during pregnancy would reduce the risk of preterm birth and achieve the maximal production of the active hormone.


Assuntos
Suplementos Nutricionais , Trabalho de Parto Prematuro/sangue , Deficiência de Vitamina D/sangue , Vitamina D/sangue , Adolescente , Adulto , Negro ou Afro-Americano , Ensaios Clínicos como Assunto , Estudos de Coortes , Feminino , Hispânico ou Latino , Humanos , Recém-Nascido , Recém-Nascido Prematuro , Trabalho de Parto Prematuro/epidemiologia , Trabalho de Parto Prematuro/etnologia , Trabalho de Parto Prematuro/prevenção & controle , Gravidez , Análise de Regressão , Risco , South Carolina , Deficiência de Vitamina D/epidemiologia , Deficiência de Vitamina D/etnologia , Deficiência de Vitamina D/prevenção & controle , População Branca
5.
J Steroid Biochem Mol Biol ; 148: 256-60, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25448734

RESUMO

There have been observational reports that maternal vitamin D status at baseline and not closest to delivery is a better predictor of pregnancy outcomes, suggesting that a cascade of events is set into motion that is not modifiable by vitamin D supplementation during later pregnancy. To address this issue, in this exploratory post-hoc analysis using correlation and logistic regression, we sought to measure the strength of the association between serum 25(OH)D concentrations at 3 timepoints during pregnancy: baseline, 1st trimester (<16 weeks); 2nd trimester (16-26 weeks); and 3rd trimester (≥27 weeks) and preterm birth. It was hypothesized that the 25(OH)D value closest to delivery would be most significantly associated with preterm birth. To accomplish this objective, the datasets from NICHD (n=333) and Thrasher Research Fund (n=154) vitamin D supplementation pregnancy studies were combined. The results of this analysis were that 25(OH)D values closer to delivery were more strongly correlated with gestational age at delivery than earlier values: 1st trimester: r=0.11 (p=0.02); 2nd trimester: r=0.08 (p=0.09); and 3rd trimester: r=0.15 (p=0.001). When logistic regression was performed with preterm birth (<37 weeks) as the outcome and 25(OH)D quartiles as the predictor variable, adjusting for study and participant race/ethnicity, as with the correlation analysis, the measurements closer to delivery were more significantly associated and had a higher magnitude of effect. That is, at baseline, those who had serum concentrations <50nmol/L (20ng/mL) had 3.3 times of odds of a preterm birth compared to those with serum concentrations ≥100nmol/L (40ng/mL; p=0.27). At 2nd trimester, the odds were 2.0 fold (p=0.21) and at the end of pregnancy, the odds were 3.8 fold (p=0.01). The major findings from this exploratory analysis were: (1) maternal vitamin D status closest to delivery date was more significantly associated with preterm birth, suggesting that later intervention as a rescue treatment may positively impact the risk of preterm delivery, and (2) a serum concentration of 100nmol/L (40ng/mL) in the 3rd trimester was associated with a 47% reduction in preterm births. This article is part of a Special Issue entitled '17th Vitamin D Workshop'.


Assuntos
Complicações na Gravidez/prevenção & controle , Nascimento Prematuro/prevenção & controle , Deficiência de Vitamina D/tratamento farmacológico , Vitamina D/sangue , Suplementos Nutricionais , Feminino , Humanos , Gravidez , Resultado da Gravidez , Fatores de Risco , Vitamina D/administração & dosagem , Deficiência de Vitamina D/sangue
7.
J Dairy Sci ; 96(1): 300-6, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23141825

RESUMO

Progesterone-releasing (controlled internal drug release, CIDR) devices inserted for 14 d are used to presynchronize the estrous cycle for timed artificial insemination (TAI) in beef heifers (14-d CIDR-PGF(2α) program). The objective was to test a similar program in dairy cows by measuring first-service conception rates (FSCR), pregnancy rates after 2 AI, and time to pregnancy compared with a control (AI after observed estrus). Postpartum cows (Holstein, Jersey, or crossbred; n=1,363) from 4 grazing dairy farms were assigned to 1 of 2 programs: 14dCIDR_TAI [CIDR in for 14 d, CIDR out, PGF(2α) injection at 19 d after CIDR removal, GnRH injection 56 h later, and then TAI 16 h later; n=737] or control [AI after observed estrus; reproductive program with PGF(2α) (cycling cows) and CIDR (noncycling cows) to synchronize estrus with the start of the breeding season; n=626]. Body condition was scored (1 to 5; thin to fat) at the start of the trial. The interval from the start of the breeding period (final PGF(2α) injection of either program) to first AI was shorter for 14dCIDR_TAI compared with the control (3.0±0.2 vs. 5.3±0.2 d; mean ± SEM) but 14dCIDR_TAI cows had lesser FSCR than controls (48 vs. 61%). Farm affected FSCR (50, 51, 67, and 58% for farms 1 to 4). The BCS affected FSCR (50, 55, and 62% for BCS=2, 2.5, and 3, respectively). Cows that either calved the year before (carryover) or that calved early in the calving season had greater FSCR than cows that calved later in the calving season (55, 61, and 42%, respectively). The percentage of cows pregnant to AI (first and second inseminations within 31-d breeding season) was similar for 14dCIDR_TAI and control (64 vs. 70%) cows, but farm (64, 62, 80, and 69%) and time of calving (70, 76, and 56%: carryover, early, and late, respectively) affected the percentage. Survival analyses showed an initial advantage for 14dCIDR_TAI (more cows inseminated and more pregnancies achieved early in the breeding season) that was not maintained over time. Conclusions were that the 14dCIDR_TAI program achieved acceptable FSCR (48%) and overall AI pregnancy rates (64%), but did not surpass a control program that used AI after observed estrus (61 and 70%, respectively).


Assuntos
Sincronização do Estro/métodos , Inseminação Artificial/veterinária , Progesterona/administração & dosagem , Animais , Bovinos , Indústria de Laticínios/métodos , Implantes de Medicamento/administração & dosagem , Implantes de Medicamento/farmacologia , Feminino , Inseminação Artificial/métodos , Gravidez/efeitos dos fármacos , Progesterona/farmacologia
8.
J Dairy Sci ; 95(9): 5102-5108, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22916915

RESUMO

Progesterone-containing devices can be inserted intravaginally for 14 d to presynchronize the estrous cycle for timed artificial insemination (TAI) in beef heifers ("14-day CIDR-PG" or "Show-Me-Synch" program). The progesterone treatment is effective for presynchronization because cattle develop a persistent dominant follicle during treatment that ovulates within 3 d after progesterone removal. The subsequent estrous cycle can be effectively used for a TAI program. Some cattle will retain a functional corpus luteum (CL) for the entire 14-d treatment period and will not be synchronized effectively because the interval to ovulation depends on the lifespan of their existing CL. The objective was to test the effect of a luteolytic dose of PGF(2α) at progesterone removal for improving synchrony of estrus after treatment and increasing conception rate to a subsequent TAI in dairy cows. Postpartum cows (n = 1,021) from 2 grazing dairy herds were assigned to 1 of 2 presynchronization programs that used a controlled internal drug releasing (CIDR) device containing progesterone: 14dCIDR (CIDR in, 14 d, CIDR out; n = 523) or 14dCIDR+PGF(2α) (CIDR in, 14 d, CIDR out, and PGF(2α); n = 498). Cows were body condition scored (BCS; 1 to 5, thin to fat) and tail painted at CIDR removal. Paint score (PS) was recorded after CIDR removal [PS = 0 (all paint removed, indication of estrus), PS = 3 (paint partially removed), or PS = 5 (no paint removed; indication of no estrus)]. At 19 d after CIDR removal, all cows were treated with PGF(2α), 56 h later treated with GnRH, and then 16 h later were TAI. Treating cows with PGF(2α) at CIDR removal increased the percentage with PS = 0 within 5 d (58.1% vs. 68.9%; 14dCIDR vs. 14dCIDR+PGF(2α)). We found no effect of treatment, however, on conception rate at TAI (41.1% vs. 43.6%; respectively). The TAI conception rate increased with increasing BCS and was greater for cows that had PS = 0 within 5 d after CIDR removal. In summary, treating cows with PGF(2α) at CIDR removal increased the percentage of cows with all tail paint removed but did not increase percentage of pregnant cows after TAI.


Assuntos
Dinoprosta/farmacologia , Sincronização do Estro/métodos , Inseminação Artificial/veterinária , Progesterona/farmacologia , Administração Intravaginal , Animais , Bovinos , Preparações de Ação Retardada/administração & dosagem , Preparações de Ação Retardada/farmacologia , Dinoprosta/administração & dosagem , Ciclo Estral/efeitos dos fármacos , Ciclo Estral/fisiologia , Feminino , Inseminação Artificial/métodos , Gravidez , Progesterona/administração & dosagem
9.
Rev Sci Tech ; 30(2): 407-16, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21961213

RESUMO

Epidemiological modelling can be a powerful tool to assist animal health policy development and disease prevention and control. Models can vary from simple deterministic mathematical models through to complex spatially-explicit stochastic simulations and decision support systems. The approach used will vary depending on the purpose of the study, how well the epidemiology of a disease is understood, the amount and quality of data available, and the background and experience of the modellers. Epidemiological models can be classified into various categories depending on their treatment of variability, chance and uncertainty (deterministic or stochastic), time (continuous or discrete intervals), space (non-spatial or spatial) and the structure of the population (homogenous or heterogeneous mixing). The increasing sophistication of computers, together with greater recognition of the importance of spatial elements in the spread and control of disease, mean that models which incorporate spatial components are becoming more important in epidemiological studies. Multidisciplinary approaches using a range of new technologies make it possible to build more sophisticated models of animal disease. New generation epidemiological models enable disease to be studied in the context of physical, economic, technological, health, media and political infrastructures. To be useful in policy development, models must be fit for purpose and appropriately verified and validated. This involves ensuring that the model is an adequate representation of the system under study and that its outputs are sufficiently accurate and precise for the intended purpose. Finally, models are just one tool for providing technical advice, and should not be considered in isolation from data from experimental and field studies.


Assuntos
Doenças dos Animais/prevenção & controle , Política de Saúde , Modelos Biológicos , Doenças dos Animais/epidemiologia , Animais , Reprodutibilidade dos Testes
10.
J Plast Reconstr Aesthet Surg ; 63(3): e253-4, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19632911

RESUMO

Hydrogen peroxide is commonly used for the decontamination of wounds. We report a case of a probable venous oxygen embolism resulting in cardiovascular collapse following irrigation of a necrotic breast wound with hydrogen peroxide. We discuss the differential diagnosis, mechanism of oxygen embolism and question the relative advantages versus disadvantages of using hydrogen peroxide for wound decontamination.


Assuntos
Anti-Infecciosos Locais/efeitos adversos , Embolia Aérea/etiologia , Parada Cardíaca/etiologia , Peróxido de Hidrogênio/efeitos adversos , Infecção da Ferida Cirúrgica/tratamento farmacológico , Irrigação Terapêutica/efeitos adversos , Administração Tópica , Anti-Infecciosos Locais/administração & dosagem , Mama , Feminino , Humanos , Peróxido de Hidrogênio/administração & dosagem , Mamoplastia/efeitos adversos , Pessoa de Meia-Idade , Infecção da Ferida Cirúrgica/etiologia
11.
J Appl Physiol (1985) ; 101(3): 789-93, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16741258

RESUMO

Cancer patients receiving radiation therapy are exposed to photon (gamma/X-ray), electron, and less commonly proton radiation. Similarly, astronauts on exploratory missions will be exposed to extended periods of lower-dose radiation from multiple sources and of multiple types, including heavy ions. Therapeutic doses of radiation have been shown to have deleterious consequences on bone health, occasionally causing osteoradionecrosis and spontaneous fractures. However, no animal model exists to study the cause of radiation-induced osteoporosis. Additionally, the effect of lower doses of ionizing radiation, including heavy ions, on general bone quality has not been investigated. This study presents data developing a murine model for radiation-induced bone loss. Female C57BL/6 mice were exposed to gamma, proton, carbon, or iron radiation at 2-Gray doses, representing both a clinical treatment fraction and spaceflight exposure for an exploratory mission. Mice were euthanized 110 days after irradiation. The proximal tibiae and femur diaphyses were analyzed using microcomputed tomography. Results demonstrate profound changes in trabecular architecture. Significant losses in trabecular bone volume fraction were observed for all radiation species: gamma, (-29%), proton (-35%), carbon (-39%), and iron (-34%). Trabecular connectivity density, thickness, spacing, and number were also affected. These data have clear implications for clinical radiotherapy in that bone loss in an animal model has been demonstrated at low doses. Additionally, these data suggest that space radiation has the potential to exacerbate the bone loss caused by microgravity, although lower doses and dose rates need to be studied.


Assuntos
Radiação Cósmica/efeitos adversos , Modelos Animais de Doenças , Íons Pesados/efeitos adversos , Osteorradionecrose/etiologia , Osteorradionecrose/fisiopatologia , Radioterapia/efeitos adversos , Animais , Calcificação Fisiológica/efeitos da radiação , Relação Dose-Resposta a Droga , Exposição Ambiental/efeitos adversos , Feminino , Radioterapia com Íons Pesados , Camundongos , Camundongos Endogâmicos C57BL , Osteoporose/etiologia , Osteoporose/fisiopatologia , Doses de Radiação , Lesões Experimentais por Radiação/etiologia , Lesões Experimentais por Radiação/fisiopatologia , Medição de Risco/métodos , Fatores de Risco
12.
J Anim Sci ; 81(7): 1830-6, 2003 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12854821

RESUMO

The purpose of the present study was to determine the effect of progesterone or progesterone + estradiol-17beta on oxytocin-induced prostaglandin F2alpha (PGF2alpha) secretion in postpartum beef cows. Thirty-four anestrous postpartum beef cows were ovariectomized (d 32 [Groups 1 to 3] or d 23 [Groups 4 to 6] postpartum [d 0 = parturition]) and allotted to six treatments (Group 1; negative control) to simulate short (Groups 2 through 5) or normal (Group 6) length estrous cycles. Steroid treatments for the respective groups were as follows: Group 1) no estradiol-17beta or progesterone treatment (n = 8; negative control); Group 2) progesterone (d 34 to 40; n = 6); Group 3) estradiol-17beta (d 32 to 33) and progesterone (d 34 to 40; n = 6); Group 4) progesterone (d 23 to 29), no estradiol-17beta (d 32 to 33), and progesterone (d 34 to 40; n = 5); Group 5) progesterone (d 23 to 29), estradiol-17beta (d 32 to 33), and progesterone (d 34 to 40; n = 5); and Group 6) progesterone (d 23 to 29), estradiol-17beta (d 32 to 33), and progesterone (d 34 to 50; n = 4; positive control). Oxytocin (100 IU) was injected (i.v.) at the end of each treatment to test the ability of the postpartum uterus to secrete PGF2alpha as measured by a stable metabolite of PGF2alpha, 15keto-13,14 dihydro-PGF2alpha (PGFM). Peak concentrations ofPGFM (P < 0.08) and total PGFM secreted (area under the curve; P < 0.05) were increased on d 6 following first (Group 2) or second (Group 4) exposure to progesterone and were similar to peak concentrations and total PGFM secreted 16 d following a simulated normal estrous cycle (Group 6). Administration of estradiol-17beta before first progesterone exposure (Group 3) did not reduce peak concentrations of PGFM or total PGFM secreted relative to the preceding groups. Peak concentrations of PGFM (P < 0.08) and total PGFM secreted (P < 0.05) were reduced following a second progesterone exposure, provided that cows were pretreated with estradiol-17beta (Group 5). In summary, oxytocin-induced release of PGFM was inhibited on d 6 following second exposure to progesterone only when cows were pretreated with estradiol-17beta. Therefore, estradiol-17beta and progesterone were both associated with the timing of PGF2, secretion in postpartum cows.


Assuntos
Bovinos/metabolismo , Dinoprosta/metabolismo , Estradiol/farmacologia , Ocitocina/farmacologia , Progesterona/farmacologia , Animais , Bovinos/fisiologia , Feminino , Fase Luteal , Ovariectomia/veterinária , Período Pós-Parto/metabolismo , Gravidez , Distribuição Aleatória
13.
Neurology ; 61(1): 71-5, 2003 Jul 08.
Artigo em Inglês | MEDLINE | ID: mdl-12847159

RESUMO

BACKGROUND: The National Institute of Neurological Disorders and Stroke (NINDS) trial reported that stroke subtype (e.g., large-artery atherothrombosis, cardioembolism, and lacunae) does not affect response to IV thrombolytic treatment. However, these conclusions were based upon stroke subtypes determined prior to extensive diagnostic evaluation. Because such initial diagnoses are frequently inaccurate, the efficacy of IV recombinant tissue plasminogen activator (rt-PA) based upon verified specific stroke subtypes remains uncertain. METHODS: The records of consecutive acute stroke patients treated with IV rt-PA at two regional stroke centers were retrospectively reviewed. The final stroke subtype after complete diagnostic evaluation was determined. The relationship between final stroke subtype and response to thrombolytic therapy was then investigated and compared with the results reported in the NINDS trial. RESULTS: Ninety consecutive patients were studied. After adjusting for baseline NIH Stroke Scale scores, no significant difference in final outcome based on confirmed stroke mechanism was identified. CONCLUSIONS: These data are consistent with those of the NINDS trial that reported that the efficacy of IV thrombolysis within the 3-hour time window is similar between different stroke subtypes. Based upon these data, allocating treatment of stroke patients with IV rt-PA based upon presumed stroke mechanism may be unnecessary. Such testing may result in time delays that could compromise the efficacy of treatment.


Assuntos
Fibrinolíticos/administração & dosagem , Acidente Vascular Cerebral/classificação , Acidente Vascular Cerebral/tratamento farmacológico , Ativador de Plasminogênio Tecidual/administração & dosagem , Resultado do Tratamento , Centros Médicos Acadêmicos/estatística & dados numéricos , Idoso , California , Hemorragia Cerebral , Feminino , Seguimentos , Hospitais Comunitários/estatística & dados numéricos , Humanos , Injeções Intravenosas , Masculino , Índice de Gravidade de Doença , Acidente Vascular Cerebral/diagnóstico , Taxa de Sobrevida , Fatores de Tempo
14.
Plast Reconstr Surg ; 108(7): 2101-5, discussion 2106-7, 2001 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11743409

RESUMO

Fibrin sealant imitates the final phase of the blood coagulation process. Fibrinogen is converted into fibrin on a tissue surface by the action of thrombin, which is then cross-linked by factor XIIIa, creating a mechanically stable fibrin network. This fibrin network is thought to reduce the amount of postoperative bleeding by sealing capillary vessels and allowing raw operative surfaces to adhere. The authors conducted a prospective, double-blind, randomized, controlled trial on the use of fibrin sealant in 20 consecutive patients undergoing bilateral face lifts by the same surgeon. Each patient was randomized for the use of fibrin sealant on either the right or the left side with the contralateral side acting as the control. Total drainage was recorded on each side for 24 hours before drains were removed. The age range of the patients in the trial (all of whom were women) was 44 to 70 years (mean, 55). The side treated with fibrin glue had a median drainage of 10 ml and the control side 30 ml. The Wilcoxon signed rank test shows a significant difference in drainage between sides (p = 0.002). The reduction in postoperative drainage could also reduce pain and bruising, increasing patient satisfaction with this procedure. The need for drains may also be obviated.


Assuntos
Adesivo Tecidual de Fibrina/uso terapêutico , Ritidoplastia/métodos , Adesivos Teciduais/uso terapêutico , Adulto , Idoso , Método Duplo-Cego , Feminino , Hemostasia Cirúrgica , Humanos , Pessoa de Meia-Idade , Complicações Pós-Operatórias , Estudos Prospectivos
15.
Br J Plast Surg ; 54(6): 543-5, 2001 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-11513520

RESUMO

In a publication climate demanding modern innovative treatments for congenital giant hairy naevi, we report a case with excellent long-term results following early surgical excision and split-thickness skin grafting.


Assuntos
Neoplasias Faciais/cirurgia , Nevo Pigmentado/cirurgia , Neoplasias Cutâneas/cirurgia , Transplante de Pele/métodos , Adulto , Estética , Neoplasias Faciais/congênito , Feminino , Seguimentos , Humanos , Recém-Nascido , Nevo Pigmentado/congênito , Neoplasias Cutâneas/congênito , Resultado do Tratamento
16.
J Biopharm Stat ; 10(3): 287-97, 2000 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10959912

RESUMO

The problem of evaluating the long-term effects of recombinant human deoxyribonuclease (rhDNase) on forced expiratory volume in one second (FEV1) in cystic fibrosis (CF) patients was considered. A two-stage mixed effects model, incorporating relevant predictive variables, captured the diverse patterns of decline of FEV1 for patients with different demographic characteristics. Based on the results of modeling the dropout process, it is clear that the probability of early dropout was closely related to patient's responsiveness to rhDNase treatment. Failure to consider the existence of informative censoring severely biased the estimates of the rate of decline and affected the interpretation of the results.


Assuntos
Fibrose Cística/tratamento farmacológico , Desoxirribonuclease I/uso terapêutico , Expectorantes/uso terapêutico , Modelos Estatísticos , Pacientes Desistentes do Tratamento/estatística & dados numéricos , Adolescente , Adulto , Criança , Pré-Escolar , Fibrose Cística/fisiopatologia , Interpretação Estatística de Dados , Desoxirribonuclease I/administração & dosagem , Método Duplo-Cego , Esquema de Medicação , Expectorantes/administração & dosagem , Feminino , Volume Expiratório Forçado/efeitos dos fármacos , Humanos , Masculino , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/uso terapêutico , Resultado do Tratamento
17.
JAMA ; 283(9): 1145-50, 2000 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-10703776

RESUMO

CONTEXT: Tissue-type plasminogen activator (tPA) is the only therapy for acute ischemic stroke approved by the Food and Drug Administration. OBJECTIVE: To assess the safety profile and to document clinical outcomes and adverse events in patients treated with intravenous tPA for acute stroke in clinical practice. DESIGN AND SETTING: Prospective, multicenter study of consecutive patients enrolled between February 1997 and December 1998 at 57 medical centers in the United States (24 academic and 33 community). INTERVENTION: Intravenous tPA (recombinant alteplase). PATIENTS: Three hundred eighty-nine patients with a mean age of 69 years (range, 28-100 years); 55% were men. MAIN OUTCOME MEASURES: Time intervals between stroke symptom onset, hospital arrival, and treatment with tPA; pretreatment computed tomographic scan results, intracerebral hemorrhage, and major systemic bleeding. The modified Rankin Scale score was used to assess clinical outcomes at 30 days. RESULTS: Median time from stroke onset to treatment was 2 hours 44 minutes, and the median baseline National Institutes of Health Stroke Scale score was 13. The 30-day mortality rate was 13%. At 30 days after treatment, 35% of patients had very favorable outcomes (modified Rankin score, 0-1) and 43% were functionally independent (modified Rankin score, 0-2). Thirteen patients (3.3%) experienced symptomatic intracerebral hemorrhage, including 7 who died. Twenty-eight patients (8.2%) had asymptomatic intracerebral hemorrhage within 3 days of treatment with tPA. Protocol violations were reported for 127 patients (32.6%), and included treatment with tPA more than 3 hours after symptom onset in 13.4%, treatment with anticoagulants within 24 hours of tPA administration in 9.3%, and tPA administration despite systolic blood pressure exceeding 185 mm Hg in 6.7%. A multivariate analysis found predictors of favorable outcome to be a less severe baseline National Institutes of Health Stroke Scale score, absence of specific abnormalities (effacement or hypodensity of >33% of the middle cerebral artery territory or a hyperdense middle cerebral artery) on the baseline computed tomographic scan, an age of 85 years or younger, and a lower mean arterial pressure at baseline. CONCLUSIONS: This study, conducted at multiple institutions throughout the United States, suggests that favorable clinical outcomes and low rates of symptomatic intracerebral hemorrhage can be achieved using tPA for stroke treatment.


Assuntos
Ativadores de Plasminogênio/uso terapêutico , Acidente Vascular Cerebral/tratamento farmacológico , Terapia Trombolítica , Ativador de Plasminogênio Tecidual/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Hemorragia Cerebral/prevenção & controle , Feminino , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Ativadores de Plasminogênio/administração & dosagem , Estudos Prospectivos , Índice de Gravidade de Doença , Acidente Vascular Cerebral/diagnóstico , Acidente Vascular Cerebral/fisiopatologia , Análise de Sobrevida , Fatores de Tempo , Ativador de Plasminogênio Tecidual/administração & dosagem , Resultado do Tratamento
18.
Control Clin Trials ; 21(1): 44-53, 2000 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10660003

RESUMO

Large-scale production of proteins by cell culture and subsequent purification for use in novel medical therapies is a slow and complex process. During the early phases of development of manufacturing processes, contamination and replication errors cause entire batches of material to be wasted. As a result, the cost of goods for large-molecule therapies in early clinical development can be significant, and the supply limited. When designing clinical trials to test expensive biological compounds with limited supply, sponsoring companies want to minimize the waste of drug, that is, to maintain small inventories of drug at the investigational hospitals. We must, however, weigh the benefits of smaller inventories against the costs of increased numbers of shipments to resupply when rapid enrollment causes shortages of drug. A well-planned randomization scheme may be able to balance these objectives. This paper demonstrates how a dynamic randomization algorithm can be used to maintain smaller drug inventory at hospitals than a typical permuted block randomization list plan, and how well it automatically restores balance when the shortage of drug causes assignment of alternate treatments.


Assuntos
Produtos Biológicos/economia , Ensaios Clínicos como Assunto/métodos , Custos de Medicamentos , Adulto , Idoso , Idoso de 80 Anos ou mais , Algoritmos , Produtos Biológicos/uso terapêutico , Ensaios Clínicos como Assunto/economia , Controle de Custos , Eficiência Organizacional , Humanos , Pessoa de Meia-Idade , Infarto do Miocárdio/tratamento farmacológico , Ativadores de Plasminogênio/economia , Ativadores de Plasminogênio/uso terapêutico , Distribuição Aleatória , Ativador de Plasminogênio Tecidual/economia , Ativador de Plasminogênio Tecidual/uso terapêutico
19.
Ann Intern Med ; 129(11): 886-90, 1998 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-9867731

RESUMO

PURPOSE: To determine the strength of clinical evidence for individual drugs as a cause of thrombocytopenia. DATA SOURCES: All English-language reports on drug-induced thrombocytopenia. STUDY SELECTION: Articles describing thrombocytopenia caused by heparin were excluded from review. Of the 581 articles reviewed, 20 were excluded because they contained no patient case reports. The remaining 561 articles reported on 774 patients. DATA EXTRACTION: Two of the authors used a priori criteria to independently review each patient case report. Two hundred fifty-nine patient case reports were excluded from further review because of lack of evaluable data, platelet count of 100000 cells/microL or more, use of cytotoxic or nontherapeutic agents, occurrence of drug-induced systemic disease, or occurrence of disease in children. For the remaining 515 patient case reports, a level of evidence for the drug as the cause of thrombocytopenia was assigned. Data on bleeding complications and clinical course were recorded. DATA SYNTHESIS: The evidence supported a definite or probable causal role for the drug in 247 patient case reports (48%). Among the 98 drugs described in these reports, quinidine was mentioned in 38 case reports, gold in 11, and trimethoprim-sulfamethoxazole in 10. Of the 247 patients described in the case reports, 23 (9%) had major bleeding and 2 (0.8%) died of bleeding. CONCLUSIONS: Many reports of drug-induced thrombocytopenia do not provide evidence supporting a definite or probable causal relation between the disease and the drug. Future patient case reports should incorporate standard criteria to clearly establish the etiologic role of the drug.


Assuntos
Trombocitopenia/induzido quimicamente , Feminino , Humanos , Masculino , Projetos de Pesquisa
20.
Anal Biochem ; 263(2): 150-7, 1998 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-9799526

RESUMO

High-throughput screening of large combinatorial chemical libraries in biochemical assays will benefit from reduced reagent volume and increased speed of measurement. Standard assays typically are performed in 96-well microtiter plates having 200-microL well volumes and up to an hour of incubation time. In this paper, we demonstrate a technique for precise and rapid measurement of the progress of an enzymatic reaction and its inhibition with reduced volume and time (for this work, the assay was mixed at the 200-microL level and detected in 2-microL volumes with minutes of total assay time). Directly measuring the enzyme activity in the small volume format yields a precise value for the median inhibitory concentration (IC50) of an inhibitor compound. The model assay is the endoproteolytic cleavage of a small fluorogenic peptide by human neutrophil collagenase (MMP-8). The fluorogenic peptide was labeled at one end with a UV/blue fluorophore (N-methylanthranilyl) and at the other end with a quencher (dinitrophenol). To generate inhibition data, a hydroxamate peptide analog inhibitor of collagenase, actinonin, was included in the reaction. The experiments were performed using ultraviolet laser illumination (325 nm wavelength) and parallel fluorescence detection by a cooled, charge-coupled-device camera system to increase sensitivity and speed. The assay volume was reduced to 2 microL for data collection, and the total time for mixing, incubation, and measurement was less than 6 min. For comparison to a standard format, the same assay was performed in a 96-well microtiter plate in 200 microL using 30 min of incubation and measurement in a microtiter plate fluorimeter. Median inhibitory concentrations (IC50) for actinonin of 73 +/- 16 and 100 +/- 14 nM were obtained in the 2- and 200-microL assays, respectively. One concern with assay miniaturization and increases in throughput is a potential loss of precision and accuracy. Laser excitation and parallel detection of fluorescence is a promising approach for increased speed and reduced cost without loss of precision for proteinase inhibition assays.


Assuntos
Inibidores de Proteases/metabolismo , Fluorescência , Humanos , Cinética , Métodos , Reprodutibilidade dos Testes
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...